Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases. Acquired by Merck in 2023.
3 investors
Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms. The company serves heart failure patients and clinicians, with operations in the United States, Australia, and Germany.
3 investors
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
3 investors
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
3 investors
Caris Lifesciences operates a precision oncology platform that analyzes DNA, RNA and proteins across tissue and blood to profile a patient's cancer and match treatments and clinical trials. It offers comprehensive molecular profiling tests, including the Caris Detect multi-cancer early detection blood test, for cancer patients and physicians.
3 investors
Cascade Biocatalysts develops engineered biocatalysts designed to be more cost efficient, reusable, and longer-lasting with a wider operating window and higher output. The company positions its biocatalysts as offering improved performance for industrial chemical and biological processes.
3 investors
Casma Therapeutics develops therapies based on targeted autophagy, using its PHLYT (Phagosome-Lysosome Targeting) platform to initiate target-specific degradation of disease-causing cellular components regardless of size or complexity. The company aims to treat diseases that current drugs have not been able to target.
3 investors
Castle Biosciences develops genomic diagnostic tests that use a patient's molecular biology to inform disease management and treatment decisions. Its tests serve healthcare providers and patients across multiple clinical focus areas to guide diagnosis, treatment, and follow-up care.
3 investors
Catalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions. Its services span oral dose, biologics, specialty, and clinical supply, from early-stage design through commercial manufacturing.
3 investors
Catena develops a conjugation platform for antibody-drug conjugates (ADCs) and multi-payload conjugates used in oncology for solid tumors. The company's technology enables therapeutic structures that deliver dual payloads to cancer targets.
3 investors
Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration. The company applies translational biology and drug development expertise across multiple therapeutic areas.
3 investors
Celerion is a contract research organization specializing in early phase clinical drug development, providing bioanalytical services and laboratory testing that generate clinical data for pharmaceutical clients. It focuses on early stage drug development to help clients make go/no-go decisions and bring drugs to market.
3 investors
3 investors
Cellarity develops therapeutics using AI-powered multi-omics analysis to identify and correct dysfunctional cellular states, treating complex diseases by regulating genetic pathways rather than targeting single genes.
3 investors
Celleste Bio develops a cell-based "cocoa technology" combining biotech, agtech, and AI to produce real cocoa ingredients—including cocoa butter and powder—at scale independent of geography and climate. Its products serve as drop-in replacements for conventional cocoa in chocolate manufacturing.
3 investors
Cellply develops VivaCyte, an automated analytical platform for characterizing immune cells at single-cell resolution, used in the discovery and process development of cell therapies. The system handles sample preparation through image processing, analyzing over 100 samples per run and more than 1,000 single cells per sample.
3 investors
Celltrion is a biopharmaceutical company that researches, develops, manufactures, and markets biosimilars and novel biologic therapeutics across therapeutic areas including immunology, oncology, hematology, ophthalmology, and endocrinology. Its products include ZYMFENTRA (subcutaneous infliximab) for inflammatory bowel disease and a range of FDA-approved biosimilars.
3 investors
CellType uses AI agents and biological models to automate drug discovery, having identified a novel cancer treatment signal and partnering with major pharmaceutical companies.
3 investors
Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.
3 investors
Centenara Labs is a longevity-focused drug discovery company that translates research on the biology of aging into therapies intended to improve healthy aging and extend lifespan. It works with a global team drawn from medical and scientific institutions to develop longevity drugs and related technologies.
3 investors
Checkerspot uses microalgae precision fermentation to produce specialized lipids and fats, including a bio-equivalent source of the sn-2 palmitate fat found in mother's milk, rare bioactive fatty acids, and tropical fat alternatives. Its ingredients serve the food, infant nutrition, and health and wellness markets, with partnerships aimed at scaling and commercializing these fats and oils.
3 investors
ChemT builds CelMo, an AI-driven virtual cell platform that models cell states and predicts responses to process, genetic, and molecular changes to optimize biomanufacturing. It applies this to CHO cells for antibody/protein production and T cell therapy manufacturing (including its Chemplify small molecule), serving biopharma teams working on cell line and process development.
3 investors
Chromologics develops natural red colorants as alternatives to synthetic dyes. Its Natu.Red product targets food and beverage manufacturers as a replacement for Red3 and Red40, while Sustainly.Red serves non-food industries such as textiles and cosmetics.
3 investors
3 investors